Chai Discovery, the artificial intelligence company pioneering the prediction and reprogramming of biochemical molecule interactions, has announced a $130 million Series B funding round co-led by Oak HC/FT and General Catalyst. The investment values the company at $1.3 billion, marking a significant milestone in its mission to accelerate drug discovery through advanced AI. The funding follows Chai’s recent breakthrough announcement, in which the company demonstrated that its latest AI models can now design molecules with critical "developability" properties—such as solubility, stability, and metabolic profile—making them more likely to succeed in clinical development. This advancement addresses a major bottleneck in traditional drug discovery, where many promising compounds fail during later stages due to poor pharmaceutical characteristics. Chai’s platform leverages deep learning to simulate and predict how molecules interact at the atomic level, enabling the design of novel therapeutics with higher precision and efficiency. By integrating physical chemistry principles with generative AI, the company is able to generate molecules that are not only effective but also practical to manufacture and deliver. The new capital will be used to expand Chai’s research and development capabilities, grow its team of AI and computational chemists, and advance its pipeline of drug candidates across multiple therapeutic areas. The company is also deepening partnerships with pharmaceutical and biotech organizations to bring AI-driven discovery into real-world drug development workflows. With this latest round, Chai joins a growing cohort of AI-powered biotech startups reshaping the future of medicine. The investment underscores increasing confidence in AI’s ability to solve complex biological challenges and deliver tangible therapeutic breakthroughs faster and more cost-effectively than traditional methods.